Pathophysiology News and Research

RSS

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.

31 Mar 2011

NUS, Agilent partner for lipidomics research

Agilent Technologies Inc. and the National University of Singapore today announced an agreement to develop expertise and knowledge in the area of analytical lipidomics. The goal of the partnership is to develop workflow solutions that enable researchers to more accurately understand disease states.

30 Mar 2011

Challenges of high-risk surgery

A small group of "high-risk" patients account for a disproportionately high number of surgery-related deaths, complications, and costs. The April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS), commences a special series on high-risk surgery—focusing on new and emerging strategies for identifying and managing patients at high risk.

28 Mar 2011

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.

28 Mar 2011

New study implicates microRNAs in panic disorder

A new study published in the current issue of Biological Psychiatry now implicates one type of molecular switch, microRNAs, in panic disorder.

25 Mar 2011

MicroRNAs may play a key role in future medicine

Since their discovery in the 1990s, microRNAs have proven to play a complex role in normal and abnormal functioning of many organ systems. In the April issue of Translational Research, entitled "MicroRNAs: A Potential New Frontier for Medicine," an international group of medical experts explores several themes related to our current understanding of microRNAs and the role they may play in the future of medicine.

24 Mar 2011

ViroPharma launches online community for teens and adults with hereditary angioedema

ViroPharma Incorporated today announced the launch of "HAE and Me," an online community that unites teens and adults with hereditary angioedema (HAE) through shared experiences to help them better manage their disease.

21 Mar 2011

Experts issue joint statement to help Americans understand radiation-related health risks

The growing concern surrounding the release of radiation from an earthquake and tsunami-stricken nuclear complex in Japan has raised fears of radiation exposure to populations in North America from the potential plume of radioactivity crossing the Pacific Ocean.

19 Mar 2011

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Genentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase III trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.

11 Mar 2011

Future Medicine launches Neuropsychiatry

Future Medicine Ltd has today announced the launch of Neuropsychiatry – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world. Neuropsychiatry is published by Future Medicine Ltd (UK, London) renowned for its collection of journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.

10 Mar 2011

NanoLogix announces MRSA testing preliminary results, new Science Advisory Board members at UTHSC

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell microorganisms, announces preliminary results of MRSA testing at the University of Texas Health Science Center - Houston. Dr. Jonathan Faro, M.D., Ph.D. has found NanoLogix technology is able to deliver results for MRSA in 6 hours, as opposed to conventional culture-based testing wait times of 24 to 48 hours.

7 Mar 2011

Journal of Chronic Obstructive Pulmonary Disease becomes official journal of COPD Foundation

COPD: Journal of Chronic Obstructive Pulmonary Disease, the first journal dedicated to publishing a range of research on the impact of COPD, has become the official journal of the COPD Foundation.

5 Mar 2011

Elsevier, CJC publish 2011 issue of Canadian Journal of Cardiology

Elsevier and the Canadian Cardiovascular Society announce the publication of the January/February 2011 issue of the Canadian Journal of Cardiology, the first in their partnership. This theme issue focused on atrial fibrillation includes the long-awaited Canadian Cardiovascular Society Atrial Fibrillation Guidelines.

21 Feb 2011

Regional brain structural alterations associated with bipolar disorder

Lithium, introduced in the late 1940's, was the first "wonder drug" in psychiatry. It was the first medication treatment for the manic and depressive episodes of bipolar disorder and it remains among one of the most effective treatments for this disorder.

17 Feb 2011

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis and Sunnybrook Health Sciences Centre announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.

16 Feb 2011

Breakthrough in cancer research can help reduce heart failure, increase survival rates

A breakthrough by scientists at Queen's University Belfast could help reduce heart failure in cancer patients around the world, and ultimately increase survival rates.

10 Feb 2011

Study finds heartburn as a common condition in Iceland

Heartburn is a signature symptom of gastroesophageal reflux disease (GERD), which is a cluster of symptoms and signs associated with regurgitation of stomach acid up to the pharynx and mouth. Patient-based studies of GERD have shown high prevalence and chronicity, particularly in Western societies. GERD is associated with significant health-care utilization and diminished quality of life.

8 Feb 2011

New report identifies top research priorities related to Female Pelvic Medicine, Reconstructive Surgery

A set of consensus recommendations identifying top research priorities related to female pelvic floor disorders is presented in the January/February issue of Female Pelvic Medicine & Reconstructive Surgery, official journal of The American Urogynecologic Society.

4 Feb 2011

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert's DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury, a major public health concern.

3 Feb 2011

Red wine polyphenols prevent ageing-induced endothelial dysfunction

The endothelium is the inner lining of our blood vessels and normal functions of endothelial cells include enabling coagulation, platelet adhesion and immune function. Endothelial dysfunction is associated with reduced anticoagulant properties and the inability of arteries and arterioles to dilate fully.

1 Feb 2011